Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
78 studies found for:    "Germinoma"
Show Display Options
Rank Status Study
1 Recruiting Chemotherapy Plus Reduced Radiotherapy in Intracranial Germinoma
Condition: Intracranial Germinoma
Interventions: Drug: Carboplatin;   Drug: Etoposide;   Drug: Cyclophosphamide;   Drug: Bleomycin;   Radiation: Reduced dose of radiotherapy
2 Recruiting Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors
Conditions: Germ Cell Tumor;   Teratoma;   Choriocarcinoma;   Germinoma;   Mixed Germ Cell Tumor;   Yolk Sac Tumor;   Childhood Teratoma;   Malignant Germ Cell Neoplasm;   Extragonadal Seminoma;   Non-seminomatous Germ Cell Tumor;   Seminoma
Interventions: Drug: paclitaxel;   Drug: ifosfamide;   Drug: cisplatin;   Drug: pegylated G-CSF;   Drug: G-CSF;   Drug: carboplatin;   Drug: etoposide phosphate;   Procedure: stem cell reinfusion
3 Recruiting Exploratory Study of Effects of Radiation Therapy in Pediatric Patients With Central Nervous System Tumors
Conditions: Diffuse Intrinsic Pontine Glioma;   PNET;   Ependymoma;   Germinoma;   Medulloblastoma
Intervention:
4 Recruiting Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors
Conditions: Childhood Central Nervous System Germ Cell Tumor;   Childhood Central Nervous System Germinoma
Interventions: Procedure: therapeutic conventional surgery;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy;   Drug: carboplatin;   Drug: etoposide;   Drug: ifosfamide
5 Terminated Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
Conditions: Childhood Atypical Teratoid/Rhabdoid Tumor;   Childhood Central Nervous System Choriocarcinoma;   Childhood Central Nervous System Germinoma;   Childhood Central Nervous System Mixed Germ Cell Tumor;   Childhood Central Nervous System Teratoma;   Childhood Central Nervous System Yolk Sac Tumor;   Childhood Choroid Plexus Tumor;   Childhood Craniopharyngioma;   Childhood Ependymoblastoma;   Childhood Grade I Meningioma;   Childhood Grade II Meningioma;   Childhood Grade III Meningioma;   Childhood Infratentorial Ependymoma;   Childhood Medulloepithelioma;   Childhood Mixed Glioma;   Childhood Oligodendroglioma;   Childhood Supratentorial Ependymoma;   Gonadotroph Adenoma;   Pituitary Basophilic Adenoma;   Pituitary Chromophobe Adenoma;   Pituitary Eosinophilic Adenoma;   Prolactin Secreting Adenoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Brain Stem Glioma;   Recurrent Childhood Central Nervous System Embryonal Tumor;   Recurrent Childhood Cerebellar Astrocytoma;   Recurrent Childhood Cerebral Astrocytoma;   Recurrent Childhood Ependymoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Pineoblastoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Childhood Spinal Cord Neoplasm;   Recurrent Childhood Subependymal Giant Cell Astrocytoma;   Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor;   Recurrent Childhood Visual Pathway and Hypothalamic Glioma;   Recurrent Childhood Visual Pathway Glioma;   Recurrent Pituitary Tumor;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   T-cell Childhood Acute Lymphoblastic Leukemia;   T-cell Large Granular Lymphocyte Leukemia;   TSH Secreting Adenoma;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097;   Other: diagnostic laboratory biomarker analysis;   Other: pharmacological study;   Drug: dexamethasone
6 Completed Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors
Conditions: Childhood Atypical Teratoid/Rhabdoid Tumor;   Childhood Central Nervous System Choriocarcinoma;   Childhood Central Nervous System Embryonal Tumor;   Childhood Central Nervous System Germinoma;   Childhood Central Nervous System Mixed Germ Cell Tumor;   Childhood Central Nervous System Teratoma;   Childhood Central Nervous System Yolk Sac Tumor;   Childhood Choroid Plexus Tumor;   Childhood Craniopharyngioma;   Childhood Ependymoblastoma;   Childhood Grade I Meningioma;   Childhood Grade II Meningioma;   Childhood Grade III Meningioma;   Childhood High-grade Cerebellar Astrocytoma;   Childhood High-grade Cerebral Astrocytoma;   Childhood Infratentorial Ependymoma;   Childhood Low-grade Cerebellar Astrocytoma;   Childhood Low-grade Cerebral Astrocytoma;   Childhood Medulloepithelioma;   Childhood Mixed Glioma;   Childhood Oligodendroglioma;   Childhood Supratentorial Ependymoma;   Extra-adrenal Paraganglioma;   Recurrent Childhood Brain Stem Glioma;   Recurrent Childhood Central Nervous System Embryonal Tumor;   Recurrent Childhood Cerebellar Astrocytoma;   Recurrent Childhood Cerebral Astrocytoma;   Recurrent Childhood Ependymoma;   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Pineoblastoma;   Recurrent Childhood Spinal Cord Neoplasm;   Recurrent Childhood Subependymal Giant Cell Astrocytoma;   Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor;   Recurrent Childhood Visual Pathway and Hypothalamic Glioma
Interventions: Drug: vorinostat;   Drug: temozolomide;   Other: diagnostic laboratory biomarker analysis;   Other: pharmacological study
7 Completed Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
Conditions: Childhood Burkitt Lymphoma;   Childhood Central Nervous System Choriocarcinoma;   Childhood Central Nervous System Germ Cell Tumor;   Childhood Central Nervous System Germinoma;   Childhood Central Nervous System Mixed Germ Cell Tumor;   Childhood Central Nervous System Teratoma;   Childhood Central Nervous System Yolk Sac Tumor;   Childhood Choroid Plexus Tumor;   Childhood Craniopharyngioma;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Medulloepithelioma;   Childhood Meningioma;   Childhood Mixed Glioma;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Childhood Oligodendroglioma;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Brain Stem Glioma;   Recurrent Childhood Central Nervous System Embryonal Tumor;   Recurrent Childhood Cerebellar Astrocytoma;   Recurrent Childhood Cerebral Astrocytoma;   Recurrent Childhood Ependymoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Malignant Germ Cell Tumor;   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Pineoblastoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Childhood Subependymal Giant Cell Astrocytoma;   Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor;   Recurrent Childhood Visual Pathway and Hypothalamic Glioma;   Recurrent Childhood Visual Pathway Glioma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: vorinostat;   Drug: bortezomib;   Other: pharmacological study;   Other: laboratory biomarker analysis
8 Completed Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment
Conditions: Childhood Central Nervous System Choriocarcinoma;   Childhood Central Nervous System Embryonal Tumor;   Childhood Central Nervous System Germ Cell Tumor;   Childhood Central Nervous System Germinoma;   Childhood Central Nervous System Mixed Germ Cell Tumor;   Childhood Central Nervous System Teratoma;   Childhood Central Nervous System Yolk Sac Tumor;   Metastatic Childhood Soft Tissue Sarcoma;   Recurrent Childhood Brain Stem Glioma;   Recurrent Childhood Central Nervous System Embryonal Tumor;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Childhood Visual Pathway Glioma;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: pazopanib hydrochloride;   Other: pharmacological study
9 Completed Sunitinib in Treating Young Patients With Refractory Solid Tumors
Conditions: Central Nervous System Metastases;   Childhood Central Nervous System Choriocarcinoma;   Childhood Central Nervous System Embryonal Tumor;   Childhood Central Nervous System Germ Cell Tumor;   Childhood Central Nervous System Germinoma;   Childhood Central Nervous System Mixed Germ Cell Tumor;   Childhood Central Nervous System Teratoma;   Childhood Central Nervous System Yolk Sac Tumor;   Recurrent Childhood Central Nervous System Embryonal Tumor;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: sunitinib malate;   Other: pharmacological study;   Procedure: dynamic contrast-enhanced magnetic resonance imaging;   Other: laboratory biomarker analysis
10 Completed Combination Chemotherapy in Treating Young Patients With Advanced Solid Tumors
Conditions: Childhood Central Nervous System Choriocarcinoma;   Childhood Central Nervous System Embryonal Tumor;   Childhood Central Nervous System Germ Cell Tumor;   Childhood Central Nervous System Germinoma;   Childhood Central Nervous System Mixed Germ Cell Tumor;   Childhood Central Nervous System Teratoma;   Childhood Central Nervous System Yolk Sac Tumor;   Recurrent Childhood Brain Stem Glioma;   Recurrent Childhood Central Nervous System Embryonal Tumor;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: oxaliplatin;   Drug: fluorouracil;   Drug: leucovorin calcium;   Other: pharmacological study;   Procedure: positron emission tomography;   Procedure: computed tomography
11 Not yet recruiting Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Conditions: Acinar Cell Carcinoma;   Adrenal Cortex Carcinoma;   Adrenal Gland Pheochromocytoma;   Anal Canal Neuroendocrine Carcinoma;   Anal Canal Undifferentiated Carcinoma;   Appendix Mucinous Adenocarcinoma;   Bladder Adenocarcinoma;   Bronchioloalveolar Carcinoma;   Cervical Adenocarcinoma;   Cervical Squamous Cell Carcinoma, Not Otherwise Specified;   Cholangiocarcinoma;   Chordoma;   Colorectal Squamous Cell Carcinoma;   Endometrial Adenocarcinoma;   Endometrioid Adenocarcinoma;   Esophageal Neuroendocrine Carcinoma;   Esophageal Undifferentiated Carcinoma;   Extrahepatic Bile Duct Carcinoma;   Fallopian Tube Adenocarcinoma;   Fibromyxoid Tumor;   Gastric Neuroendocrine Carcinoma;   Gastric Squamous Cell Carcinoma;   Giant Cell Carcinoma;   Intestinal Neuroendocrine Carcinoma;   Intrahepatic Cholangiocarcinoma;   Lung Carcinoid Tumor;   Lung Sarcomatoid Carcinoma;   Major Salivary Gland Carcinoma;   Malignant Odontogenic Neoplasm;   Malignant Peripheral Nerve Sheath Tumor;   Malignant Skin Neoplasm;   Malignant Testicular Sex Cord-Stromal Tumor;   Metastatic Malignant Neoplasm of Unknown Primary Origin;   Mixed Mesodermal (Mullerian) Tumor;   Mucinous Adenocarcinoma;   Mucinous Cystadenocarcinoma;   Nasal Cavity Adenocarcinoma;   Nasal Cavity Carcinoma;   Nasopharyngeal Carcinoma;   Nasopharyngeal Papillary Adenocarcinoma;   Nasopharyngeal Undifferentiated Carcinoma;   Oral Cavity Carcinoma;   Oropharyngeal Undifferentiated Carcinoma;   Ovarian Adenocarcinoma;   Ovarian Germ Cell Tumor;   Ovarian Mucinous Adenocarcinoma;   Ovarian Squamous Cell Carcinoma;   Pancreatic Acinar Cell Carcinoma;   Pancreatic Neuroendocrine Carcinoma;   Paraganglioma;   Paranasal Sinus Adenocarcinoma;   Paranasal Sinus Carcinoma;   Parathyroid Gland Carcinoma;   Pituitary Gland Carcinoma;   Placental Choriocarcinoma;   Placental-Site Gestational Trophoblastic Tumor;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Pseudomyxoma Peritonei;   Scrotal Squamous Cell Carcinoma;   Seminal Vesicle Adenocarcinoma;   Seminoma;   Serous Cystadenocarcinoma;   Small Intestinal Adenocarcinoma;   Small Intestinal Squamous Cell Carcinoma;   Spindle Cell Neoplasm;   Squamous Cell Carcinoma of the Penis;   Teratoma With Malignant Transformation;   Testicular Non-Seminomatous Germ Cell Tumor;   Thyroid Gland Carcinoma;   Tracheal Carcinoma;   Transitional Cell Carcinoma;   Undifferentiated Gastric Carcinoma;   Ureter Adenocarcinoma;   Ureter Squamous Cell Carcinoma;   Urethral Adenocarcinoma;   Urethral Squamous Cell Carcinoma;   Vaginal Adenocarcinoma;   Vaginal Squamous Cell Carcinoma, Not Otherwise Specified;   Vulvar Adenocarcinoma;   Vulvar Squamous Cell Carcinoma
Interventions: Procedure: Biospecimen Collection;   Biological: Ipilimumab;   Biological: Nivolumab
12 Enrolling by invitation TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors
Conditions: Ovarian Germ Cell Cancer;   Ovarian Neoplasms;   Ovarian Cancer
Interventions: Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Bleomycin;   Drug: Etoposide;   Drug: Cisplatin
13 Active, not recruiting Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Conditions: Ovarian Endometrioid Adenocarcinoma;   Ovarian Seromucinous Carcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Serous Surface Papillary Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Ovarian Germ Cell Tumor;   Recurrent Primary Peritoneal Carcinoma;   Undifferentiated Ovarian Carcinoma
Interventions: Drug: Everolimus;   Other: Laboratory Biomarker Analysis;   Drug: Letrozole
14 Recruiting Metformin Hydrochloride and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Brenner Tumor;   Malignant Ascites;   Malignant Pleural Effusion;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Ovarian Germ Cell Tumor;   Recurrent Primary Peritoneal Cavity Cancer;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Ovarian Germ Cell Tumor;   Stage IIIA Primary Peritoneal Cavity Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Ovarian Germ Cell Tumor;   Stage IIIB Primary Peritoneal Cavity Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Ovarian Germ Cell Tumor;   Stage IIIC Primary Peritoneal Cavity Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor;   Stage IV Primary Peritoneal Cavity Cancer
Interventions: Drug: paclitaxel;   Drug: carboplatin;   Drug: docetaxel;   Drug: metformin hydrochloride;   Drug: placebo;   Other: laboratory biomarker analysis
15 Active, not recruiting Scripted Sexual Health Informational Intervention in Improving Sexual Function in Patients With Gynecologic Cancer
Conditions: Anxiety Disorder;   Cervical Cancer;   Endometrial Cancer;   Female Reproductive Cancer;   Gestational Trophoblastic Tumor;   Ovarian Epithelial Cancer;   Ovarian Germ Cell Tumor;   Sexual Dysfunction;   Uterine Sarcoma;   Vaginal Cancer;   Vulvar Cancer
Interventions: Other: informational intervention;   Other: counseling intervention;   Other: questionnaire administration
16 Withdrawn Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Ovarian Papillary Serous Carcinoma;   Ovarian Serous Cystadenocarcinoma;   Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Ovarian Germ Cell Tumor;   Recurrent Primary Peritoneal Cavity Cancer
Interventions: Drug: metformin hydrochloride;   Drug: carboplatin;   Drug: paclitaxel;   Other: laboratory biomarker analysis
17 Recruiting Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery
Conditions: Male Breast Cancer;   Recurrent Melanoma;   Stage IV Breast Cancer;   Stage IV Melanoma;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor;   Unspecified Adult Solid Tumor, Protocol Specific;   Hepatocellular Carcinoma
Interventions: Drug: propranolol hydrochloride;   Other: Correlative Studies
18 Withdrawn Palliative Care in Improving Quality of Life and Symptoms in Patients With Stage III-IV Pancreatic or Ovarian Cancer
Conditions: Recurrent Ovarian Epithelial Cancer;   Recurrent Ovarian Germ Cell Tumor;   Recurrent Pancreatic Cancer;   Stage III Pancreatic Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Ovarian Germ Cell Tumor;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Ovarian Germ Cell Tumor;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Ovarian Germ Cell Tumor;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor;   Stage IV Pancreatic Cancer
Interventions: Other: palliative care;   Behavioral: educational intervention;   Procedure: quality-of-life assessment;   Other: questionnaire administration;   Behavioral: telephone-based intervention
19 Recruiting Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, and Urologic Cancers
Conditions: Healthy, no Evidence of Disease;   Localized Transitional Cell Cancer of the Renal Pelvis and Ureter;   Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter;   Psychosocial Effects of Cancer and Its Treatment;   Recurrent Bladder Cancer;   Recurrent Cervical Cancer;   Recurrent Colon Cancer;   Recurrent Gastric Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Ovarian Germ Cell Tumor;   Recurrent Pancreatic Cancer;   Recurrent Rectal Cancer;   Recurrent Renal Cell Cancer;   Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter;   Recurrent Urethral Cancer;   Recurrent Uterine Sarcoma;   Regional Transitional Cell Cancer of the Renal Pelvis and Ureter;   Stage II Bladder Cancer;   Stage II Renal Cell Cancer;   Stage II Urethral Cancer;   Stage IIA Cervical Cancer;   Stage IIA Colon Cancer;   Stage IIA Gastric Cancer;   Stage IIA Ovarian Epithelial Cancer;   Stage IIA Ovarian Germ Cell Tumor;   Stage IIA Pancreatic Cancer;   Stage IIA Rectal Cancer;   Stage IIA Uterine Sarcoma;   Stage IIB Cervical Cancer;   Stage IIB Colon Cancer;   Stage IIB Gastric Cancer;   Stage IIB Ovarian Epithelial Cancer;   Stage IIB Ovarian Germ Cell Tumor;   Stage IIB Pancreatic Cancer;   Stage IIB Rectal Cancer;   Stage IIB Uterine Sarcoma;   Stage IIC Colon Cancer;   Stage IIC Ovarian Epithelial Cancer;   Stage IIC Ovarian Germ Cell Tumor;   Stage IIC Rectal Cancer;   Stage III Bladder Cancer;   Stage III Pancreatic Cancer;   Stage III Renal Cell Cancer;   Stage III Urethral Cancer;   Stage IIIA Cervical Cancer;   Stage IIIA Colon Cancer;   Stage IIIA Gastric Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Ovarian Germ Cell Tumor;   Stage IIIA Rectal Cancer;   Stage IIIA Uterine Sarcoma;   Stage IIIB Cervical Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Gastric Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Ovarian Germ Cell Tumor;   Stage IIIB Rectal Cancer;   Stage IIIB Uterine Sarcoma;   Stage IIIC Colon Cancer;   Stage IIIC Gastric Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Ovarian Germ Cell Tumor;   Stage IIIC Rectal Cancer;   Stage IIIC Uterine Sarcoma;   Stage IV Bladder Cancer;   Stage IV Gastric Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor;   Stage IV Pancreatic Cancer;   Stage IV Renal Cell Cancer;   Stage IV Urethral Cancer;   Stage IVA Cervical Cancer;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVA Uterine Sarcoma;   Stage IVB Cervical Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer;   Stage IVB Uterine Sarcoma;   Ureter Cancer
Interventions: Other: educational intervention;   Behavioral: telephone-based intervention;   Procedure: quality-of-life assessment;   Other: questionnaire administration
20 Terminated
Has Results
Palifosfamide in Treating Patients With Recurrent Germ Cell Tumors
Conditions: Adult Central Nervous System Germ Cell Tumor;   Adult Teratoma;   Malignant Extragonadal Germ Cell Tumor;   Malignant Extragonadal Non-Seminomatous Germ Cell Tumor;   Extragonadal Seminoma;   Recurrent Malignant Testicular Germ Cell Tumor;   Recurrent Ovarian Germ Cell Tumor;   Stage IV Extragonadal Non-Seminomatous Germ Cell Tumor;   Stage IV Extragonadal Seminoma;   Stage IV Ovarian Germ Cell Tumor
Intervention: Drug: palifosfamide

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years